Trial Profile
Phase II Study of Ofatumumab in Combination With High Dose Methylprednisolone Followed by Ofatumumab and Lenalidomide Consolidative Therapy for the Treatment of Relapsed or Refractory CLL/SLL The HiLOG Trial
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Sep 2023
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Methylprednisolone (Primary) ; Ofatumumab (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- Acronyms HiLOG
- 02 Apr 2021 Status changed from active, no longer recruiting to completed.
- 02 Jun 2020 Planned End Date changed from 1 May 2021 to 1 Dec 2021.
- 02 Jun 2020 Planned primary completion date changed from 1 May 2020 to 1 Dec 2020.